Cargando…
Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
Alzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia. Aggregation of the amyloid-β peptide (Aβ) plays an important role in the disease, with Aβ oligomers representing the most toxic species. Previously, we have developed the Aβ oligomer eliminating therapeutic compound RD2 co...
Autores principales: | Elfgen, Anne, Hupert, Michelle, Bochinsky, Kevin, Tusche, Markus, González de San Román Martin, Estibaliz, Gering, Ian, Sacchi, Silvia, Pollegioni, Loredano, Huesgen, Pitter F., Hartmann, Rudolf, Santiago-Schübel, Beatrix, Kutzsche, Janine, Willbold, Dieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450887/ https://www.ncbi.nlm.nih.gov/pubmed/30952881 http://dx.doi.org/10.1038/s41598-019-41993-6 |
Ejemplares similares
-
The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
por: van Groen, Thomas, et al.
Publicado: (2017) -
Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination
por: Klein, Antonia Nicole, et al.
Publicado: (2016) -
In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease
por: Schartmann, Elena, et al.
Publicado: (2018) -
Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1(G93A) Transgenic Mice
por: Post, Julia, et al.
Publicado: (2021) -
QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers
por: Brener, Oleksandr, et al.
Publicado: (2015)